Nancy Maltez, University of Ottawa

Research

Car-T Cells Immunotherapy Scleroderma Systemic Sclerosis

Latest papers

Identifying candidate core domains for clinical trials in systemic sclerosis-associated Raynaud's phenomenon and digital ulcers.
Seminars in arthritis and rheumatism · 2026
Recognising and managing polymyalgia rheumatica.
BMJ (Clinical research ed.) · 2026
Assessing the diagnostic utility of baseline creatine kinase levels in patients with suspected idiopathic inflammatory myopathies and neuromuscular disorders.
Rheumatology advances in practice · 2026

All 37 publications

Latest funding

Canadian-Made CD19 CAR-T Therapy for Refractory Systemic Sclerosis, from the Canadian Led Immunotherapies Collaborative (CLIC-03 Trial)
CIHR · 2025 · Principal investigator
$1,216,351

All 1 grants and awards

37 publications.

01

Identifying candidate core domains for clinical trials in systemic sclerosis-associated Raynaud's phenomenon and digital ulcers.

Proudman SM, Hughes M, Maltez N, Brown E, Hickey V, Quinn KA, Christensen R, Shea B, Herrick AL, Pauling JD, Merkel PA, OMERACT Scleroderma Vascular Disease Working Group

Seminars in arthritis and rheumatism2026

DOI: 10.1016/j.semarthrit.2026.153009 PMID: 42269228

02

Recognising and managing polymyalgia rheumatica.

Rosenberg H, Maltez N, Rangwala S, Long B

BMJ (Clinical research ed.)2026

DOI: 10.1136/bmj-2026-407803 PMID: 42508833

03

Assessing the diagnostic utility of baseline creatine kinase levels in patients with suspected idiopathic inflammatory myopathies and neuromuscular disorders.

Wilk N, Pinheiro FO, Renken L, Molina-Esteban N, Kodishala C, Ivory C, Maltez N, Gupta L, Lilleker JB, Chinoy H

Rheumatology advances in practice2026

DOI: 10.1093/rap/rkag061 PMID: 42369244

04

Successful corticosteroid-free management of anti-HMG-CoA reductase immune-mediated necrotizing myopathy with subcutaneous immunoglobulins monotherapy: a case report.

Wilk N, Cowan J, Booth RA, Warman-Chardon J, Maltez N, Ivory C

Journal of medical case reports2026

DOI: 10.1186/s13256-026-06218-1 PMID: 42304511

05

Spectrum of Ocular Manifestations in Anti-Synthetase Syndrome: A Case Report and Systematic Review.

Sriranganathan A, Dhillon J, Stasso J, Maltez N, Tadrous C, Gottlieb CC

Ocular immunology and inflammation2026

DOI: 10.1080/09273948.2026.2626815 PMID: 41642723

06

Two case reports of eosinophilic fasciitis with onset after immune checkpoint inhibitor cessation.

Theriau CF, Maltez N, Hosseini N, Petkiewicz S, Song X, Ong M

Frontiers in oncology2026

DOI: 10.3389/fonc.2026.1613243 PMID: 41858366

07

Points to consider for reporting digital ulcers in systemic sclerosis interventional studies: An initiative from the world Scleroderma Foundation digital ulcer ad hoc committee.

Campochiaro C, Maltez N, Suliman Y, Alunno A, Alcacer-Pitarch B, Allanore Y, Baron M, Chung L, Del Galdo F, Denton CP, Distler O, Furst D, Galetti I, Giuggioli D, Khanna D, Krieg T, Moinzadeh P, Kuwana M, Matucci-Cerinic M, Pope J, Hughes M

Autoimmunity reviews2026

DOI: 10.1016/j.autrev.2026.104010 PMID: 41740914

08

Improving Knowledge Dissemination of Rheumatic Toxicities of Cancer Immunotherapy: A Web-Based Educational Initiative.

Roberts J, Jamal S, Hudson M, Katz S, Ennis D, Maltez N, Lau K, Ye C

Musculoskeletal care2025

DOI: 10.1002/msc.70065 PMID: 39947713

09

Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment.

Storwick J, Ye C, Jamal S, Maltez N, Chan M

Pediatric rheumatology online journal2025

DOI: 10.1186/s12969-025-01127-x PMID: 40665314

10

Improvement in Skin Fibrosis and Lung Function with Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis.

Maltez N, Wang M, Wells GA, Tugwell P, Baron M, Marjanovic Z, Lansiaux P, Farge D, Hudson M

Transplantation and cellular therapy2025First author

DOI: 10.1016/j.jtct.2025.02.005 PMID: 39938806

Canadian-Made CD19 CAR-T Therapy for Refractory Systemic Sclerosis, from the Canadian Led Immunotherapies Collaborative (CLIC-03 Trial)

Principal investigatorCIHR2025Project Grant

Principal investigators: Kekre, Natasha; Hay, Kevin A; Holt, Rob; Hudson, Marie; Maltez, Nancy

Keywords: Car-T Cells; Immunotherapy; Scleroderma; Systemic Sclerosis

$1,216,351

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Medicine
Department of Medicine
Psychiatry
Rheumatology
Department of Epidemiology and Biostatistics
Epidemiology and Public Health
School of Epidemiology and Public Health
Other

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: Car-T Cells Dear Professor Maltez, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Identifying candidate core domains for clinical trials in systemic sclerosis-associated Raynaud's phenomenon and digital ulcers." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Canadian-Made CD19 CAR-T Therapy for Refractory Systemic Sclerosis, from the Canadian Led Immunotherapies Collaborative (CLIC-03 Trial)" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]